155 related articles for article (PubMed ID: 11041273)
1. Involvement of other neurotransmitters in behaviors induced by the cannabinoid CB1 receptor antagonist SR 141716A in naive mice.
Darmani NA; Pandya DK
J Neural Transm (Vienna); 2000; 107(8-9):931-45. PubMed ID: 11041273
[TBL] [Abstract][Full Text] [Related]
2. Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids.
Janoyan JJ; Crim JL; Darmani NA
Pharmacol Biochem Behav; 2002; 71(1-2):155-62. PubMed ID: 11812518
[TBL] [Abstract][Full Text] [Related]
3. The cannabinoid CB1 receptor antagonist SR 141716A induces penile erection by increasing extra-cellular glutamic acid in the paraventricular nucleus of male rats.
Succu S; Mascia MS; Sanna F; Melis T; Argiolas A; Melis MR
Behav Brain Res; 2006 May; 169(2):274-81. PubMed ID: 16516985
[TBL] [Abstract][Full Text] [Related]
4. Behaviorally active doses of the CB1 receptor antagonist SR 141716A increase brain serotonin and dopamine levels and turnover.
Darmani NA; Janoyan JJ; Kumar N; Crim JL
Pharmacol Biochem Behav; 2003 Jul; 75(4):777-87. PubMed ID: 12957219
[TBL] [Abstract][Full Text] [Related]
5. Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis.
Darmani NA; Johnson JC
Eur J Pharmacol; 2004 Mar; 488(1-3):201-12. PubMed ID: 15044052
[TBL] [Abstract][Full Text] [Related]
6. The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats.
Solinas M; Panlilio LV; Antoniou K; Pappas LA; Goldberg SR
J Pharmacol Exp Ther; 2003 Jul; 306(1):93-102. PubMed ID: 12660305
[TBL] [Abstract][Full Text] [Related]
7. The cannabinoid receptor antagonist SR-141716A induces penile erection in male rats: involvement of paraventricular glutamic acid and nitric oxide.
Melis MR; Succu S; Mascia MS; Sanna F; Melis T; Castelli MP; Argiolas A
Neuropharmacology; 2006 Feb; 50(2):219-28. PubMed ID: 16288932
[TBL] [Abstract][Full Text] [Related]
8. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice.
McMahon LR; Koek W
Eur J Pharmacol; 2007 Aug; 569(1-2):70-6. PubMed ID: 17553486
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoids of diverse structure inhibit two DOI-induced 5-HT(2A) receptor-mediated behaviors in mice.
Darmani NA
Pharmacol Biochem Behav; 2001 Feb; 68(2):311-7. PubMed ID: 11267636
[TBL] [Abstract][Full Text] [Related]
10. Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain.
Adams IB; Compton DR; Martin BR
J Pharmacol Exp Ther; 1998 Mar; 284(3):1209-17. PubMed ID: 9495885
[TBL] [Abstract][Full Text] [Related]
11. The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2.
Darmani NA
Eur J Pharmacol; 2001 Oct; 430(1):49-58. PubMed ID: 11698062
[TBL] [Abstract][Full Text] [Related]
12. Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A.
Darmani NA
Neuropsychopharmacology; 2001 Feb; 24(2):198-203. PubMed ID: 11120402
[TBL] [Abstract][Full Text] [Related]
13. Cannabinoid modulation of intestinal propulsion in mice.
Colombo G; Agabio R; Lobina C; Reali R; Gessa GL
Eur J Pharmacol; 1998 Feb; 344(1):67-9. PubMed ID: 9570450
[TBL] [Abstract][Full Text] [Related]
14. Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain.
Rinaldi-Carmona M; Pialot F; Congy C; Redon E; Barth F; Bachy A; Brelière JC; Soubrié P; Le Fur G
Life Sci; 1996; 58(15):1239-47. PubMed ID: 8614277
[TBL] [Abstract][Full Text] [Related]
15. The silent and selective 5-HT1A antagonist, WAY 100635, produces via an indirect mechanism, a 5-HT2A receptor-mediated behaviour in mice during the day but not at night. Short communication.
Darmani NA
J Neural Transm (Vienna); 1998; 105(6-7):635-43. PubMed ID: 9826108
[TBL] [Abstract][Full Text] [Related]
16. Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A.
Aceto MD; Scates SM; Lowe JA; Martin BR
Eur J Pharmacol; 1995 Aug; 282(1-3):R1-2. PubMed ID: 7498260
[TBL] [Abstract][Full Text] [Related]
17. (R)-Methanandamide and delta9-tetrahydrocannabinol-induced operant rate decreases in rats are not readily antagonized by SR-141716A.
Järbe TU; Lamb RJ; Liu Q; Makriyannis A
Eur J Pharmacol; 2003 Apr; 466(1-2):121-7. PubMed ID: 12679148
[TBL] [Abstract][Full Text] [Related]
18. Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat.
Navarro M; Hernández E; Muñoz RM; del Arco I; Villanúa MA; Carrera MR; Rodríguez de Fonseca F
Neuroreport; 1997 Jan; 8(2):491-6. PubMed ID: 9080435
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid receptor.
Ruiu S; Pinna GA; Marchese G; Mussinu JM; Saba P; Tambaro S; Casti P; Vargiu R; Pani L
J Pharmacol Exp Ther; 2003 Jul; 306(1):363-70. PubMed ID: 12663689
[TBL] [Abstract][Full Text] [Related]
20. Discriminative stimulus effects of the cannabinoid antagonist, SR 141716A, in delta -sup-9-tetrahydrocannabinol-treated rhesus monkeys.
McMahon LR; France CP
Exp Clin Psychopharmacol; 2003 Nov; 11(4):286-93. PubMed ID: 14599262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
